Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Errata - English

PDF CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
URSODIOL TABLETS IMPURITIES/Organic Impurities/Procedure USP36–NF31 5520 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Sample solution: Change
Tablets, equivalent to about 25 mg of ursodiol,
to:
Tablets, equivalent to about 250 mg of ursodiol,
SORBITAN MONOPALMITATE IDENTIFICATION/A. USP36–NF31 2213 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Sample: Change
1 g of the residue obtained in the Assay for Fatty Acids
to:
Residue obtained in the Assay for Fatty Acids
AND
Line 2 of Acceptance criteria: Change
210–225
to:
210–225 on 1-g sample
BETHANECHOL CHLORIDE IMPURITIES/Heavy Metals, Method 1 <231> Second Supplement to USP36–NF31 6568 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Test preparation: Change
Bethacholine Chloride
to:
Bethanechol Chloride
POWDERED STINGING NETTLE COMPOSITION/Content of Total Amino Acids USP36–NF31 1606 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
MEPROBAMATE TABLETS ASSAY/Procedure First Supplement to USP36–NF31 6015 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 4 of Standard solution: Change
Dissolve in 30% of the final flask volume, and dilute with water to volume.
to:
Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume.
BETAMETHASONE SODIUM PHOSPHATE Identification/B. Thin-Layer Chromatographic Identification Test <201> USP36–NF31 2645 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Test solution: Change
1 mg per mL.
to:
1 mg per mL in methanol.
DACARBAZINE FOR INJECTION USP Reference standards <11> USP36–NF31 3137 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of USP Dacarbazine Related Compound B RS: Change
C4H3N5O 137.10
to:
C4H3N5O · H2O 155.12
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 5: Delete
Titrimetric system
(See Titrimetry <541>.)
Mode: Direct titration
Titrant: 0.1 N sodium hydroxide VS
Endpoint detection: Visual
LAMOTRIGINE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 1 USP36–NF31 4056 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 3 of Standard solution: Change
0.028 µg/mL
to:
0.028 mg/mL
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities/Table 2 USP36–NF31 5438 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote c: Change
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
to:
1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More
PURIFIED GYMNEMA EXTRACT COMPOSITION/Content of Gymnemic Acids First Supplement to USP36–NF31 5884 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria: Change
90%–110% of the labeled amount
to:
90.0%–110.0% of the labeled amount on the dried basis
SODIUM HYDROXIDE ASSAY/Procedure USP36–NF31 2203 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
= volume of Titrant consumed by the Sample to the first endpoint (mL)
to:
= volume of Titrant consumed by the Sample to the second endpoint (mL)
CLARITHROMYCIN FOR ORAL SUSPENSION ASSAY/Procedure USP36–NF31 3018 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Change the subsection head
Buffer:
to:
Buffer A:
AND
After the Buffer A subsection: Add
Buffer B: 0.067 M dibasic potassium phosphate
AND
Line 1 of Mobile phase: Change
Methanol and Buffer
to:
Methanol and Buffer ARead More
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
FEXOFENADINE HYDROCHLORIDE TABLETS ASSAY/Procedure USP36–NF31 3576 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 6 of Sample stock solution: Change
(equivalent to 80% of the total flask volume)
to:
(sufficient to fill the flask to 80% of its volume)
NIFEDIPINE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 4/Instrumental conditions USP36–NF31 4509 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Cell: Change
0.5 cm
to:
1 cm
GYMNEMA IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system First Supplement to USP36–NF31 5880 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Adsorbent: Change
5m
to:
5 µm
POWDERED STINGING NETTLE EXTRACT COMPOSITION/Content of Total Amino Acids USP36–NF31 1608 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
OXCARBAZEPINE IMPURITIES/Organic Impurities, Procedure 1 First Supplement to USP36–NF31 6035 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 4 of Column 1 of Table 1: Change
Dibenzazepinoneb
to:
Oxcarbazepine related compound E
AND
Delete footnote b
AND
Reletter the following footnotes in both the table and footnote definitions:
c to b
d to c
e to d
CALCIUM CARBONATE IMPURITIES USP36–NF31 2747 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria in Limit of Fluoride: Change
50 ppm
to:
NMT 50 ppm
AND
Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change
0.5 ppm
to:
NMT 0.5 ppm
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE Total collagen content USP36–NF31 3155 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 7 of Collagen calibration standards: Change
by adding 25 mL, 50 mL, 100 mL, and 200 mL,
to:
by adding 25 μL, 50 μL, 100 μL, and 200 μL,
EDETATE DISODIUM ASSAY/Procedure USP36–NF31 3370 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 16 of Analysis: Change
Calculate the percentage of edetate disodium
to:
Calculate the weight of edetate disodium
AND
Line 19 of Analysis: Change
Result = (VT/VU) × W × (Mr1/Mr2) ×… Read More
LEVOFLOXACIN ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 4099 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of USP Levofloxacin Related Compound A RS: Change
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid.
to:
(S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-… Read More
VENLAFAXINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5551 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
STINGING NETTLE COMPOSITION/Content of Total Amino Acids USP36–NF31 1604 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Reagent solution: Change
Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin,
to:
Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
GENTAMICIN SULFATE IMPURITIES/Limit of Methanol First Supplement to USP36–NF31 5990 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Analysis: Change
Result = (RU/RS) × (CS/CU) × D × F × 100
to:
Result = (RU/RS) × (CS Read More
AMOXICILLIN IMPURITIES/Organic Impurities/Procedure USP36–NF31 2477 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Acceptance criteria: Change
[Note—The reporting limit is 0.03% of the amoxicillin peak from the Standard solution. ]
to:
[Note—The reporting limit is 0.03 times the amoxicillin peak from the Standard solution. ]
CLARITHROMYCIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 4 USP36–NF31 3019 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Standard solution: Change
and Medium (96:4).
to:
and Medium (4:96).
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION Assay USP36–NF31 3277 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
FLUPHENAZINE DECANOATE INJECTION Assay USP36–NF31 3639 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 11 of Standard preparation: Delete
(1:5)
AND
Line 8 of Assay preparation: Delete
(1:5)
OLMESARTAN MEDOXOMIL IMPURITIES/Organic Impurities/Impurity Table USP36–NF31 4570 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Footnote d: Change
((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate.
to:
(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More
POWDERED GYMNEMA IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system First Supplement to USP36–NF31 5883 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Adsorbent: Change
5m
to:
5 µm
GLYCERYL DISTEARATE ASSAY/Procedure/Chromatographic system USP36–NF31 2029 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Column temperature: Change
Column temperature: 40°
to:
Temperatures
Detector: 40°
Column: 40°
OXCARBAZEPINE IMPURITIES/Organic Impurities, Procedure 2 First Supplement to USP36–NF31 6035 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 9 of Column 1 of Table 3: Change
Oxcarbazepine related compound Eg
to:
Oxcarbazepine related compound E
AND
Delete footnote g
CEFDINIR CAPSULES IMPURITIES/Organic Impurities/Table 2 USP36–NF31 2850 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 16 of Column 1: Change
Cefdinir impurity 2e
to:
Cefdinir impurity 2f
AND
Row 21 of Column 1: Change
Cefdinir impurity 3e
to:
Cefdinir impurity 3f
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES Assay USP36–NF31 3276 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride.
to:
Mobile phase—Prepare a solution of acetonitrile, water,… Read More
FELBAMATE TABLETS IMPURITIES/Organic Impurities/System suitability/Suitability requirements USP36–NF31 3537 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Resolution: Change
NMT 2
to:
NLT 2
MOXIFLOXACIN OPHTHALMIC SOLUTION Related compounds USP36–NF31 4414 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Row 1 of Column 3 of Table 2: Change
Relative Retention Time vs. Moxifloxacin
to:
Relative Retention vs. Moxifloxacin
AND
Row 1 of Column 3 of Table 3: Change
Relative Retention Time vs. Moxifloxacin
to:
Relative Retention vs. Moxifloxacin
VENLAFAXINE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP36–NF31 5554 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 2 of Venlafaxine Related Compound A RS: Change
1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol.
C16H25NO2
263.38
to:
1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride.
C16H25NO2… Read More
ALBUTEROL SULFATE Chromatographic purity USP36–NF31 2352 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1: Change
It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution.
to… Read More
MINOCYCLINE HYDROCHLORIDE CAPSULES Assay USP36–NF31 4375 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More
NIFEDIPINE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP36–NF31 4509 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1 of Solution A: Change
Dissolve 330.9 mg of sodium phosphate
to:
Dissolve 330.9 g of dibasic sodium phosphate
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION Assay for potassium USP36–NF31 4834 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Potassium stock solution and Standard preparations
to:
Standard stock solution and Standard solutions
AND
Line 1 of Procedure: Change
for Procedure in the Assay under Potassium Chloride Oral Solution.
to… Read More
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS Dissolution <711> USP36–NF31 4841 1-Jun-2013 USP37–NF32 USP37–NF32 Line 5: Change
Potassium stock solution
to:
Standard stock solution
AND
Line 7: Change
Prepare as directed for Standard preparations
to:
Prepare as directed for Standard solutions
AND
Line 7 of Procedure: Change
for Read More
THIMEROSAL TOPICAL AEROSOL SPECIFIC TESTS/Alcohol Determination, Method II <611> USP36–NF31 5369 1-Jun-2013 USP37–NF32 USP37–NF32 Line 4 of Analysis: Change
Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone.
to:
Read More
CARAWAY OIL DEFINITION USP36–NF31 1924 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3: Change
It contains NMT 50.0% of d-carvone (C10H14O).
to:
It contains NLT 50.0% of d-carvone (C10H14O).
NORTRIPTYLINE HYDROCHLORIDE IMPURITIES/Organic Impurities First Supplement to USP36–NF31 6027 1-Jun-2013 USP37–NF32 USP37–NF32 Line 3 of Acceptance criteria: Change
Standard solution
to:
Sample solution
FOSPHENYTOIN SODIUM INJECTION USP Reference standards <11> USP36–NF31 3680 1-Jun-2013 USP37–NF32 USP37–NF32 Line 6: Change
C14H15NO2
to:
C14H13NO2
MINOCYCLINE HYDROCHLORIDE TABLETS Assay USP36–NF31 4378 1-Jun-2013 USP37–NF32 USP37–NF32 Line 2: Change
Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride.
to:
Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More
PENTAZOCINE INJECTION Chemical Information USP36–NF31 4734 1-Jun-2013 USP37–NF32 USP37–NF32 Line 1: Remove all chemical information.